GraftWorx Wins Preclinical In-Kind Services from Surpass as Part of the Rosenman Institute's 2015 Innovation Award
July 31, 2019
Emerging Medical Device Company, GraftWorx, Wins Preclinical In-Kind Services from Surpass as Part of the Rosenman Institute's 2015 Innovation Award.
OSCEOLA, WI and MOUNTAIN VIEW, CA (PRNewswire-iReach) - Surpass, Inc. ("Surpass"), a recognized leader in preclinical research services for the medical device industry, announced today that GraftWorx won in-kind services from Surpass as part of the recent Rosenman Institute's Innovation Awards. The Rosenman Institute, an initiative of California life science accelerator QB3, accelerates the development of medical devices by pairing early-stage medical device entrepreneurs with experienced medical device professionals and valuable resources. The goal of the Rosenman Innovation Awards is to propel those promising ideas towards commercialization.
"The Surpass team is committed to being present, visible and involved in the biomedical communities where we do business. By offering Surpass' preclinical in-kind services as part of this award, we help drive medical innovation companies beyond early-stage financing challenges. The preclinical proof-of-concept data generated de-risk the opportunity for potential investors and ultimately help advance these life-improving products into the hands of physicians and patients," says Surpass CEO, Tim Pelura, PhD. "Not only does Surpass provide the research services through the entire study process but we also assist entrepreneurs during due diligence to better the chances of moving their technologies forward into the clinic. By supporting programs like QB3 and the Rosenman Institute Innovation Awards, together we can advance value-driven innovation and ensure the health of the medical innovation continuum."
GraftWorx is turning the Internet of Things into the Internet of the Body by enabling current vascular prostheses such as stents and bypass grafts to become "smart." They build smart prosthetics and then leverage their cloud-based algorithms to improve patient's lives. Their first product is expected to save 40,000 amputations in the US each year, a cost savings of hundreds of millions of dollars. "We are grateful to receive preclinical services as part of the Rosenman Institute's Innovation Award," said David Kuraguntla, GraftWorx Founder and CEO. "The data generated from this award will complete the package necessary to obtain later stage financing for our "smart-prosthetic" technology and ultimately support our product launch into the clinic."
